Ovid Therapeutics (OVID) Current Leases (2022 - 2026)

Ovid Therapeutics' Current Leases history runs 5 years deep, the most recent figure standing at $1.5 million for Q1 2026.

• Quarterly Current Leases rose 7.28% year-over-year to $1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 million (up 7.28% YoY) and the FY2025 annual result came in at $1.4 million, up 7.26% from the prior year.
• Current Leases was $1.5 million for Q1 2026 at Ovid Therapeutics, up from $1.4 million in the prior quarter.
• Across five years, Current Leases topped out at $1.5 million in Q1 2026 and bottomed at $533946.0 in Q4 2022.
• A 5-year average of $1.2 million and a median of $1.3 million in 2024 frame the typical range for Current Leases.
• Annual changes were most pronounced in 2023 — Current Leases jumped 133.36% — and 2025, when it increased 7.2%.
• Ovid Therapeutics' Current Leases stood at $533946.0 in 2022, then soared by 133.36% to $1.2 million in 2023, then increased by 7.22% to $1.3 million in 2024, then gained by 7.26% to $1.4 million in 2025, then climbed by 1.81% to $1.5 million in 2026.
• Business Quant data shows OVID's Current Leases at $1.5 million in Q1 2026, $1.4 million in Q4 2025, and $1.4 million in Q3 2025.